What is Jw?
Established in 2016, Jw Therapeutics operates as an independent, innovative biotechnology firm dedicated to the research, production, and commercialization of cell immunotherapy products. The company has engineered a comprehensive, proprietary platform that addresses a diverse spectrum of medical challenges, including hematological malignancies, solid tumors, and various autoimmune conditions. By maintaining a rigorous focus on high-quality breakthrough therapies, Jw Therapeutics is not only addressing critical unmet medical needs in China but is also positioning itself as a pivotal player in the global cell therapy landscape. Its public listing on the Hong Kong Stock Exchange serves as a testament to its operational maturity and its commitment to standardized, scalable healthcare innovation.
How much funding has Jw raised?
Jw has raised a total of $190M across 2 funding rounds:
Series A
$90M
Series B
$100M
Series A (2018): $90M with participation from Temasek
Series B (2020): $100M led by CPE and Mirae Asset
Key Investors in Jw
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
CPE
CPE is a leading private equity firm in China that focuses on long-term value creation through strategic investments in healthcare, technology, and consumer sectors.
Mirae Asset
Mirae Asset is a global financial services group that provides comprehensive investment management and advisory services across diverse asset classes and international markets.
What's next for Jw?
With the capital secured through its recent financing rounds, Jw Therapeutics is well-positioned to accelerate its clinical pipeline and expand its manufacturing capabilities. The strategic focus will likely shift toward the commercialization of its lead assets and the further refinement of its cell immunotherapy platform to ensure long-term competitive advantage. As the company navigates the complexities of the global oncology market, the integration of its therapeutic solutions into standard clinical practice will be the primary driver of its future valuation. Investors will be closely monitoring the firm's ability to translate its robust development platform into sustained revenue growth and improved patient outcomes on a global scale.
See full Jw company page
